SPC239
Secúkínúmab
Status:
AfturkölluðApplication date:
10.10.2018Application published:
15.10.2018
Max expiry date:
3.8.2030Medicine name:
Cosentyx - secukinumabMedicine for children:
No
Timeline
Today
10.10.2018Application
15.10.2018Publication
3.8.2030Expires
Marketing license
Foreign authorization number:
EU/1/14/980Date:
19.11.2015
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, Basel CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2902039